EcoDrugPlus

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSVPAG00000001864
Gene Symbol: PSMD1
1 Cross references
210 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 11

Ensembl ID : ENSVPAG00000002523
Gene Symbol: PSMD11
1 Cross references
285 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSVPAG00000001849
Gene Symbol: PSMD12
1 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 13

Ensembl ID : ENSVPAG00000003507
Gene Symbol: PSMD13
1 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 14

Ensembl ID : ENSVPAG00000002718
Gene Symbol: PSMD14
1 Cross references
213 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 6

Ensembl ID : ENSVPAG00000010081
Gene Symbol: PSMD6
1 Cross references
212 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 7

Ensembl ID : ENSVPAG00000002042
Gene Symbol: PSMD7
1 Cross references
243 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 8

Ensembl ID : ENSVPAG00000002127
Gene Symbol: PSMD8
1 Cross references
202 Possible Orthologues:

Protein Arginine Methyltransferase 5

Ensembl ID : ENSVPAG00000000600
Gene Symbol: PRMT5
1 Cross references
198 Possible Orthologues:

Protein Kinase C Alpha

Ensembl ID : ENSVPAG00000006398
Gene Symbol: PRKCA
1 Cross references
289 Possible Orthologues:

Protein Kinase C Beta

Ensembl ID : ENSVPAG00000006456
Gene Symbol: PRKCB
1 Cross references
284 Possible Orthologues:

Protein Kinase C Epsilon

Ensembl ID : ENSVPAG00000006827
Gene Symbol: PRKCE
1 Cross references
316 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).